Transgene is a fully integrated biopharmaceutical company that designs and develops cutting-edge immunotherapeutic products to treat cancers and chronic infectious diseases. Our expertise covers all stages of product development, from research to the manufacture of clinical batches, and the conducting of clinical trials.
Four products are currently in clinical development: TG4010 having completed phase II trials, TG4001/RG3484 in phase IIb trial, TG4040 in phase II trial and TG4023 in phase I trial.
Transgene has concluded strategic agreements with two major pharmaceutical companies:
-
with Roche for the development of TG4001/RG3484 to treat HPV-mediated diseases
-
with Novartis for the development of TG4010 to treat various cancers
Transgene is also a partner in a major, externally funded, research project (ADNA program) that aims to achieve individualized medicine for cancers, infectious diseases and genetic diseases. The program focuses on the identification and development of biological markers, and its findings are already making a substantial contribution to the future development of our products.
The company has a number of exclusive and innovative technologies using viral vectors. Its proprietary gene transfer technology is protected by an extensive portfolio of intellectual property rights.
Transgene is committed to scientific excellence and medical innovation, with the company’s top level scientists focusing on applying their research findings to developing new therapies in order to treat unmet medical needs. A strong pre-clinical pipeline bears witness to this commitment.
For over 25 years Transgene has built on its recognized scientific expertise. Today, we are a major player in the field of immunotherapy.